EGFR and non-small cell lung carcinoma: Pts with stage IIIB-IV NSCLC and without EGFR activating mutation and ALK rearrangement;KN046 +axitinib; treatment-naive and PD-L1 expression ≥1%, N=44; treatment-naive and PD-L1 expression ≥50%, N=15; progressed on CPIs, N=32);